QLSF Biotherapeutics

Executive Summary

QLSF Biotherapeutics is a private immuno-oncology company headquartered in San Diego, founded in 2020, that discovers next-generation antibody-based therapeutics for cancer. The company specializes in designing multispecific antibodies and cytokine fusions that simultaneously engage adaptive and innate immune systems to address challenging targets. Its pipeline is supported by a leading pharmaceutical partner, providing validation and development expertise. The company is currently in Phase 1/2 clinical development, focusing on bispecific antibodies that modulate the tumor microenvironment. QLSF's approach aims to overcome resistance mechanisms and improve patient outcomes across multiple solid tumor indications. With a diversified portfolio and strategic collaborations, the company is positioned to deliver innovative therapies that combine checkpoint inhibition with immune activation. The early clinical data and continued partnership support underscore its potential to become a significant player in the immuno-oncology space, though the typical risks of early-stage biotech remain.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data readout for lead bispecific antibody40% success
• Q4 2026Initiation of Phase 2 expansion cohort in a new indication60% success